138 related articles for article (PubMed ID: 19688212)
21. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
22. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation.
Weber DM
Oncology (Williston Park); 2003 Jun; 17(6):765-7. PubMed ID: 12846120
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
[TBL] [Abstract][Full Text] [Related]
25. Bulbar palsy in multiple myeloma.
Chim CS; Ooi GC
Haematologica; 2005 Dec; 90(12 Suppl):ECR42. PubMed ID: 16464757
[No Abstract] [Full Text] [Related]
26. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
27. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
28. Therapy-resistant leg ulcer caused by multiple myeloma.
Bago A; Schweiter J; Kiss M; Furesz J; Vajda A; Balo-Banga JM
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):647-8. PubMed ID: 16164734
[No Abstract] [Full Text] [Related]
29. Myeloma researchers gain genome, new targets, and new concerns.
Brower V
J Natl Cancer Inst; 2011 Jul; 103(14):1082-5. PubMed ID: 21737696
[No Abstract] [Full Text] [Related]
30. Treatment options and considerations for the newly diagnosed myeloma patient.
Rajkumar VS;
Oncology (Williston Park); 2005 Sep; 19(10):1260, 1262, 1267 passim. PubMed ID: 16285223
[No Abstract] [Full Text] [Related]
31. Novel agents in first-line therapy for myeloma.
Jagannath S
Oncology (Williston Park); 2005 Nov; 19(12):1551-4. PubMed ID: 16396150
[No Abstract] [Full Text] [Related]
32. Simultaneous presentation and following remission of chronic lymphocytic leukemia and multiple myeloma.
Bernardeschi P; Bonechi I; Marchetti G; Puglisi R
Recenti Prog Med; 1995 Jan; 86(1):25. PubMed ID: 7709037
[No Abstract] [Full Text] [Related]
33. Chemotherapy-associated thrombosis.
Ashrani AA; Rajkumar SV
Cancer Treat Res; 2009; 148():181-206. PubMed ID: 19377925
[No Abstract] [Full Text] [Related]
34. Treatment of multiple myeloma in patients with Gaucher disease.
Machaczka M; Lerner R; Klimkowska M; Hägglund H
Am J Hematol; 2009 Oct; 84(10):694-6. PubMed ID: 19743447
[No Abstract] [Full Text] [Related]
35. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
36. Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes.
Giuliani N; Caramatti C; Roti G; Geata A; Colla S; Bonomini S; Hojden M; La Monica S; Sammarelli G; Lazzaretti M; Craviotto L; Mangoni L; Rizzoli V
J Clin Oncol; 2003 May; 21(9):1887-8. PubMed ID: 12721268
[No Abstract] [Full Text] [Related]
37. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
38. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
SanMiguel J; Facon T; Cavo M
Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204
[No Abstract] [Full Text] [Related]
39. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
[No Abstract] [Full Text] [Related]
40. Infiltration of the spinal cord in a patient with multiple myeloma.
Varettoni M; Corso A; Zappasodi P; Calliada F; Castagnola C; Mangiacavalli S; Lazzarino M
J Clin Oncol; 2008 Sep; 26(25):4207-9. PubMed ID: 18757337
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
